Date | Price Target | Rating | Analyst |
---|---|---|---|
7/18/2024 | $646.00 → $530.00 | Buy → Neutral | BofA Securities |
6/24/2024 | $643.00 | Overweight | Morgan Stanley |
5/30/2024 | $649.00 | Outperform | Robert W. Baird |
3/6/2024 | $584.00 | Overweight | Barclays |
7/12/2023 | Outperform → Peer Perform | Wolfe Research | |
4/27/2023 | $500.00 → $571.00 | Equal-Weight → Overweight | Morgan Stanley |
4/21/2023 | $547.00 | Overweight | Cantor Fitzgerald |
3/28/2023 | $523.00 → $572.00 | Sector Perform → Outperform | RBC Capital Mkts |
Elevance Health's (NYSE:ELV) short percent of float has fallen 4.08% since its last report. The company recently reported that it has 2.19 million shares sold short, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes
Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $600 price target.
Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $600 to $593.
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)
BofA Securities downgraded Elevance Health from Buy to Neutral and set a new price target of $530.00 from $646.00 previously
Morgan Stanley initiated coverage of Elevance Health with a rating of Overweight and set a new price target of $643.00
Robert W. Baird initiated coverage of Elevance Health with a rating of Outperform and set a new price target of $649.00
10-Q - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
11-K - Elevance Health, Inc. (0001156039) (Filer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut
Paragon doubles revenues and increases the number of infusion centers by 400% during Peak Rock's ownership AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private investment firm, announced today it has signed a definitive agreement for the sale of Paragon Healthcare, Inc. ("Paragon" or the "Company") to Elevance Health (NYSE:ELV). Paragon is a leading provider of ambulatory and home infusion services as well as specialty pharmacy services. The Company provides comprehensive, high quality infusion services to patients with chronic health conditions and those in need of post-acute care. Headquartered in Plano, Texas, with m
Mark Kaye named Executive Vice President, Chief Financial Officer Elevance Health (NYSE:ELV) announced today that John Gallina will retire from his role as executive vice president and CFO later this year. Mark Kaye has been named executive vice president and CFO and will serve as a member of the company's executive leadership team, reporting directly to Gail K. Boudreaux, President and CEO. Kaye will serve as CFO Designate from September 6 to November 1, 2023, when he will assume full responsibility for the role. Gallina will remain with Elevance Health serving as Special Advisor to the CEO following his retirement as CFO to ensure a seamless transition. Gallina's distinguished career
2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported second quarter 2024 results. "Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which
Elevance Health (NYSE:ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-391-9851 – No Access Code (Domestic Replay) 203-369-3268 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2024, until the end of the day on August 17, 2024. The call w
1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 1Q 2024 diluted EPS1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS2 of $10.64, up 12.5% FY 2024 diluted EPS and adjusted diluted EPS guidance raised to greater than $34.05 and $37.20, respectively Launching strategic partnership to advance primary care and physician enablement Elevance Health, Inc. (NYSE:ELV) reported first quarter 2024 results. "First quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry. We are making significant progress expanding Carelon's capabilities, scaling our flywheel for enterprise growth, and delivering results fo
Whole Health Index is an industry-leading calculation for defining and measuring the most powerful drivers of individual and community health The Whole Health Index (WHI), created by Elevance Health, Inc. (NYSE:ELV) physicians, data scientists, and researchers, is a first-of-its-kind assessment of health. Using a scale of 0 to 100, the WHI can evaluate a person or group's relative health over time and assess the physical, behavioral, and social factors that influence it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802170993/en/Here are a few examples that illustrate how Elevance Health-affiliated plans can use community-
Indianapolis charter school received first ever fitness space, strength training clinics and curriculum Irvington Preparatory Academy today unveiled their first ever weight room and fitness space, provided by Elevance Health in partnership with the Impact Fitness Foundation (IFF), a national nonprofit that provides fitness resources to schools. The facility upgrade marks the third Indianapolis high school to receive a new fitness space in celebration of the Elevance Health Women's Fort Myers Tip-Off, a pre-season collegiate basketball tournament that takes place in November. At Elevance Health, the strategy to become a lifetime trusted health partner is fueled by their purpose to improv
2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported second quarter 2024 results. "Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which